Observational Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. May 15, 2022; 14(5): 1037-1049
Published online May 15, 2022. doi: 10.4251/wjgo.v14.i5.1037
Table 1 Patients’ characteristics
Patient No.
Age (yr)
Sex
Indication for LT
Post-LT time (mo)
Stent placement status
Number of previous ERCPs
142MHepatitis B liver cirrhosis25Y3
255MAlcoholic liver cirrhosis6Y1
355MAlcoholic liver cirrhosis9Y1
452MHepatitis B liver cirrhosis7Y1
547MCryptogenic liver cirrhosis11N0
663FHepatitis C liver cirrhosis6N0
752FPrimary biliary cholangitis17Y2
852FHepatitis B liver cirrhosis36Y3
944MAlcoholic liver cirrhosis26N0
1037FDrug-induced liver injury, acute liver failure2N0
1137FDrug-induced liver injury, acute liver failure4Y1
1254MAlcoholic liver cirrhosis4N1
1342MHepatitis B liver cirrhosis, acute liver failure30N0
1454MHepatocellular carcinoma/hepatitis B17Y2
1572FCryptogenic liver cirrhosis20N0
1641FPrimary biliary cholangitis21N0
1759MCryptogenic liver cirrhosis13N0
1849MAlcoholic liver cirrhosis15N0
1949MHepatitis B liver cirrhosis17Y0